Peripheral arterial disease: A high risk - But neglected - Disease population

BMC Cardiovascular Disorders

Volumn 5, Issue , 2005, Pages

  Tomson, Joseph ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; RAMIPRIL; TICLOPIDINE;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTERY SURGERY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; META ANALYSIS; MORBIDITY; MORTALITY; NON INVASIVE MEASUREMENT; NOTE; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; STROKE; SYSTEMATIC REVIEW; AGE; CARDIOVASCULAR DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE;

AGE FACTORS; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; PERIPHERAL VASCULAR DISEASES; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX FACTORS;

EID: 26844498756     PISSN: 14712261     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-5-15     Document Type: Note

References (17)

1. Meijer WT, Grobbee DE, Hunink MG, et al.: Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 2000, 160:2934-2938.
2. Reunanen A, Takkunen H, Aromaa A: Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1982, 211:249-256.
3. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T: Fate in intermittent claudication: outcome and risk factors. Br Med J 1986, 293:1137-1140.
4. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D: The prevalence of peripheral arterial disease in a defined population. Circulation 1985, 71:510-515.
5. Caro JJ, Migliaccio-Walle K, Ishak KJ, Proskorovsky I: The morbidity and mortality following a diagnosis of peripheral arterial disease: Long-term follow-up of a large database. BMC Cardiovascular Disorders 2005, 5:14.
6. Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group: Management of peripheral arterial disease (PAD). J Vasc Surg 2000, 31:S1-S296.
7. Criqui MH, Langer RD, Fronek A, et al.: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992, 326:381-386.
8. Conway DS, Lip GY: Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol 2004, 93(11):1422-5.
9. Weitz JI, Byrne J, Clagett GP, et al.: Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996, 94:3026-3049.
10. Hirsch AT, Criqui MH, Treat-Jacobson D, et al.: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286:1317-1324.
11. Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001, 344:1608-1621.
12. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Prevention of AtherothromboticDisease Network, et al.: Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003, 163(8):884-92.
13. Leng GC, Price JF, Jepson RG: Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev 2000:CD000123.
14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al.: the Treating to New Targets (TNT) Investigators. N Engl J Med 2005, 352:1425-1435.
15. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, for the CAMELOT Investigators: Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure: The CAMELOT Study: A Randomized Controlled Trial. JAMA 2004, 292:2217-2225.
16. Antiplatelet Trialists' Collaboration: Collaboration overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81-106.
17. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.